A simple and efficient method for the synthesis of 4-tosyloxazoles from tosylmethyl isocyanide with α-ketoimidoyl chlorides

Mahdiyeh Talebizadeh,*, Ali Darehkordi,* and Mohammad Anary-Abbasinejad* 

*Department of Chemistry, Faculty of Science, Vali-e-Asr University of Rafsanjan, Rafsanjan 77176, Iran
E-mail: darehkordi@vru.ac.ir, adarehkordi@yahoo.com

Received 03-07-2018, Accepted 05-21-2018, Published on line 06-17-2018

Abstract

An efficient one-pot method for the synthesis of potentially biologically active 4-tosyloxazole derivatives is described via reaction of imidoyl chloride adducts generated in situ from the reaction of isocyanide and acyl chlorides with p-toluenesulfonylmethyl isocyanide (TosMIC). This reaction was carried out in the presence of sodium hydride as a base and in THF to produce 4-tosyloxazoles in excellent yield.

Keywords: 4-Tosyloxazoles, α-ketoimidoyl chloride, tosylmethyl isocyanide, oxazole
Introduction

Oxazole compounds have attracted much attention due to their emergence as subunits of interesting biological and pharmacological compounds with anticancer\textsuperscript{1,2}, antibacterial\textsuperscript{3,4}, anti-inflammatory\textsuperscript{5,6} and antitubercular activities.\textsuperscript{7-10} Also, these compounds are used as valuable precursors in many useful synthetic transformations.\textsuperscript{11-13} Oxazoles are commonly synthesized using the Hantzsch reaction\textsuperscript{14,15} or by cyclodehydration of ketoamides.\textsuperscript{16-19} Synthesis via dehydration of 2-acylaminoketones is an important method for the preparation of a wide range of 2,5-disubstituted and 2,4,5-trisubstituted oxazole derivatives.\textsuperscript{20,21} Alkyl isocyanocacetates, methyl isocyanocacetate were exploited by different groups towards the synthesis of 5-substituted oxazole derivatives as well as 5-(aminomethyl) oxazoles.\textsuperscript{22-26} Sasaki prepared bisoxazole derivatives which were substituted at the 4-position and dioxazolo metacyclophane derivatives using TosMIC.\textsuperscript{27} Oxazole derivatives with substitution at the 5-position were synthesized by cyclocondensation of aldehydes with monosubstituted tosylmethyl isocyanide in moderate yield\textsuperscript{28-39} and by reaction of aryl aldehydes with TosMIC and also metalated methyl isocyanides.\textsuperscript{40-44} Although there are many methods for the synthesis of oxazoles,\textsuperscript{45-48} few approaches are available for the preparation of 4,5-disubstituted oxazoles.\textsuperscript{28-39} Reaction of α-diazo-β-keto- carboxylates and -phosphonates with arene carboxamides gives 2-aryloxazole-4-carboxylates and 4-phosphonates by carbene N–H insertion, followed by cyclodehydration results in the formation of oxazole-5-carboxylates and 5-phosphonates.\textsuperscript{49} NIS-mediated iodocyclization of N-sulfonyl propargylamides is developed for the synthesis of various oxazolidines and iodoalkylidenedihydrooxazoles via a 5-exo-dig process.\textsuperscript{46} According to this investigation and literature reports \textsuperscript{50,29} reactions directly arising from acid chlorides are useful and high yielding methods for synthesis of functionalized oxazoles.

Results and Discussion

A literature search revealed that only 5-phenyl-4-tosyloxazole has been synthesized from reaction of benzoyl chloride and TosMIC in the presence of K\textsubscript{2}CO\textsubscript{3} as base in dimethoxyethane at 20 °C, but the yield of this reaction is low (50-55\%)\textsuperscript{39} (Scheme 1).

\begin{center}
\textbf{Scheme 1.} Methods for the synthesis of 4-tosyloxazoles.
\end{center}
Due to the importance of oxazoles in medicinal chemistry and drug discovery, and also, in continuation of our work to develop syntheses of heterocyclic compounds from imidoyl chlorides, we were looking to synthesize 4-tosyloxazole derivatives by condensation of aromatic and aliphatic α-ketoimidoyl chlorides with cyclohexyl isocyanide. In this work, we report a simple method for the synthesis of 4-tosyloxazole derivatives by condensation of aromatic and aliphatic α-ketoimidoyl chlorides with TosMIC in THF as solvent in excellent yields without using any catalyst. The Nef isocyanide adducts obtained from addition of isocyanide with aromatic or aliphatic acyl chloride was reacted at ambient temperature with TosMIC to afford 5-phenyl-4-tosyloxazole (5a, Scheme 2).

In search for selective and efficient conditions, different solvent such as THF, CH$_3$CN and CH$_2$Cl$_2$ (at room temperature and reflux conditions) and also a variety of bases, including K$_2$CO$_3$, NaH, and Et$_3$N were studied. As mentioned in Table 1, in the presence of Et$_3$N or K$_2$CO$_3$ (in THF solvent at room temperature and reflux conditions) and also in the presence of K$_2$CO$_3$ (in CH$_2$Cl$_2$ solvent at room temperature), we did not obtain any products (Table 1, entries 1–5). But when NaH was used as a base in THF or CH$_3$CN at room temperature, the corresponding product was produced in excellent yields (entry 6-7). Therefore, all of the reactions were performed in THF in the presence of NaH at room temperature. To extend the scope of the reaction, the optimized protocol was applied for the synthesis of 4-tosyloxazoles by reaction with different imidoyl chlorides. α-Ketoimidoyl chlorides bearing various electron-donating functional groups at various positions reacted with TosMIC (2) smoothly and the corresponding compounds (5a-i) were obtained in excellent yield (Table 2). But α-ketoimidoyl chlorides with electron-withdrawing functional groups such as 4-NO$_2$-C$_6$H$_4$, 3-NO$_2$-C$_6$H$_4$, pyridin-4-yl, EtO$_2$CCO and MeO$_2$CCO in the same reaction conditions, did not produce any products. The results are summarized in Table 2.

**Table 1. Model reaction, conditions and yields**

| Entry | Solvent | Base   | Conditions     | Yield (%) |
|-------|---------|--------|----------------|-----------|
| 1     | THF     | NEt$_3$| 25 °C, 24 h    | -         |
| 4     | THF     | K$_2$CO$_3$| Reflux, 24 h | -         |
| 5     | CH$_2$Cl$_2$ | K$_2$CO$_3$ | 25 °C, 24 h | -         |
| 6     | THF     | NaH    | 25 °C, 45min   | 90        |
| 7     | CH$_3$CN| NaH    | 25 °C, 45min   | 89        |
Table 2. Synthesis of 4-tosyloxazole derivatives from tosylmethyl isocyanide and α- ketoimidoyl chlorides

| Entry | R           | Product | Melting point (°C) | Isolated Yield (%) |
|-------|-------------|---------|--------------------|--------------------|
| 1     | C₆H₅        | 5a      | 134-135            | 90                |
| 2     | 4-BrC₆H₄    | 5b      | 153-155            | 98                |
| 3     | 4-FC₆H₄     | 5c      | 214-216            | 96                |
| 4     | 3-FC₆H₄     | 5d      | 193-195            | 96                |
| 5     | 3-ClC₆H₄    | 5e      | 260-262            | 97                |
| 6     | 4-MeC₆H₄    | 5f      | 281-282            | 96                |
| 7     | 3-MeC₆H₄    | 5g      | 270-272            | 95                |
| 8     | CH₃OCH₂     | 5h      | 200-212            | 98                |
| 9     | Cl(CH₃)₂CCHCl| 5i      | 180-182            | 98                |
| 10    | 4-NO₂C₆H₄   | 5j      | -                  | -                 |
| 11    | 3-NO₂C₆H₄   | 5k      | -                  | -                 |
| 12    | pyridin-4-yl| 5l      | -                  | -                 |
| 13    | EtO₂CCO     | 5m      | -                  | -                 |
| 14    | MeO₂CCO     | 5n      | -                  | -                 |

A possible mechanism is proposed in Scheme 2. The formation of 4-tosyloxazole 5 by reaction of cyclohexyl isocyanide, acyl chloride and TosMIC can be rationalized by initial formation of the ketoimidoyl chloride adducts 3 by the reaction of cyclohexyl isocyanide 1 with acyl chlorides 2. Then, the intermediate 3 is attacked by TosMIC 4 to form the intermediate A, which then undergoes an intramolecular cyclization reaction to afford product 5 (Scheme 2).

Scheme 2. Plausible mechanism for the synthesis of 4-tosyloxazole.

According to the mechanism reaction, the second step (intramolecular cyclization reaction of intermediate A to product 5) is suggested to be very important. So, the electron-donating groups on the α-
ketoimidoyl chlorides increase the reaction rate and the electron-withdrawing groups on the α-ketoimidoyl chlorides decrease the reaction rate. The structures of compounds 5a-i were deduced by the IR, NMR spectral and elemental analytical data. For example the 1H-NMR spectrum of 5a exhibited a singlet at δ= 8.90 due to the oxazole proton. Multiplet at δ= 7.85-7.61, doublet at δ= 7.84, JHH= 8.0 Hz, multiplet at δ= 7.59-7.61 and doublets at δ= 7.46, JHH= 8.2 Hz correspond to nine aromatic protons present in the molecule. The signal a δ= 2.41 was assigned to the methyl protons. The 13C-NMR spectrum of 5a displayed a downfield signal at δ= 152.22 for the carbon C2 of the oxazole ring and at δ= 21.60 for methyl carbon.

Conclusions

In summary, the reaction of ketoimidoyl chlorides with TosMIC in THF in the presence of sodium hydride (NaH) as base at room temperature provides a facile and efficient route for the synthesis of 4-tosyloxazole derivatives in excellent yields. The advantages of this method are high yield, readily available starting materials, simple procedure and a straightforward purification of the products.

Experimental Section

General. 1H-NMR spectra were recorded in DMSO-d6 on a Bruker model DRX-400 AVANCE spectrometer (400 MHz) with TMS as internal standard 13C-NMR spectra were taken a by a Bruker model DRX-400 AVANCE (100 MHz) spectrometer. Chemical shifts are given in ppm relative to TMS, the coupling constants J are given in Hz. Melting points were determined on a Melt-Tem II melting point apparatus and are uncorrected. IR spectra were obtained on a Thermo scientific, Nicolet is10 FT-IR spectrometer. Peaks are reported in wave numbers (cm⁻¹). Element analyses (CHN) were performed with a EUROVECTOR EuroEA3000 CHNSO analyzer.

Lenochka, d has to be italic (not 6). Could you please change in all Experimental Section. Thanks.

General procedure for the synthesis of compounds 5a-i

In a typical experimental procedure, a dry, two-necked, 50 mL round bottomed flask was charged with 1.0 mmol of acyl chloride derivatives and 1.0 mmol of cyclohexyl isocyanide and heated at 60 °C for 1 h. Then a mixture of TosMIC (1.0 mmol) and sodium hydride (60% w/w) (1.0 mmol) in THF (10 ml) was added. The mixture was stirred at room temperature for 45 min. After completion of the reaction, as indicated by TLC (ethyl acetate : n-hexane = 1 : 3), the solvent was evaporated at reduced pressure; the precipitate was washed with diethyl ether (10 ml) and was recrystallized from 95% ethanol to afford pure products 5a-i.

5-Phenyl-4-tosyloxazole (5a). Light yellow solid, mp 134-135°C (Yield: 98%). IR (KBr) (υmax, cm⁻¹): 1595 (C=N), 1314, 1144 (S=O). 1H-NMR (400 MHz, DMSO-d6): δ (ppm) 2.41 (3H, s, CH3), 7.46 (2H, d, JHH 8.1 Hz, HAr), 7.59-7.61 (3H, m, HAr), 7.84 (2H, d, JHH 8.1 Hz, HAr), 7.89-7.91 (2H, m, HAr), 8.90 (1H, s, oxazole proton). 13C-NMR (100 MHz, DMSO-d6): δ (ppm) 21.60 (CH3), 125.74, 125.98, 128.53, 128.71, 129.16, 129.42, 130.55, 131.49, 137.19, 145.56, 152.22 (C=N). Calcd. For (C16H13NO3S): C, 64.18; H, 4.39; S, 10.70%. Found: C, 64.20; H, 4.38; N, 4.68; S, 10.71%.

5-(4-Bromophenyl)-4-tosyloxazole (5b). Colorless crystals, mp 153-155 °C (Yield: 90%). IR (KBr) (υmax, cm⁻¹): 1594 (C=N), 1332, 1149 (S=O). 1H-NMR (400 MHz, DMSO-d6): δ (ppm) 2.40 (3H, s, CH3), 7.47 (2H, d, JHH 8.1 Hz, HAr), 7.83-7.85 (6H, m, HAr), 8.68 (1H, s, oxazole proton). 13C-NMR (100 MHz, DMSO-d6): δ (ppm) 21.60 (CH3), 124.95, 125.24, 128.32, 130.58, 131.39, 132.25, 135.45, 136.98, 145.68, 151.29, 152.44 (C=N). Calcd. for (C16H12BrNO3S): C, 50.83; H, 30.19; N, 3.71; S, 8.49%. Found: C, 50.81; H, 30.20; N, 3.70; S, 8.48%.
5-(4-Fluorophenyl)-4-tosyloxazole (5c). Yellow solid, mp 214 -216°C (Yield: 98%). IR (KBr) (υmax, cm⁻¹): 1609 (C=N) 1329, 1149 (S=O). ³H- NMR (400 MHz, DMSO-d₆): δ (ppm) 2.41 (3H, S, CH₃), 7.43-7.48 (4H, m, HAr), 7.84 (2H, d, ßJHH 8.1 Hz, HAr), 7.96 (2H, dd, ßJHH 8.2 Hz, ßJHH 4 Hz, HAr), 8.66 (1H, s, oxazole proton); ¹³C NMR (100 MHz, DMSO-d₆): δ (ppm) 21.59 (CH₃), 116.36 (d, ßJC 22.0 Hz), 122.31, 128.27, 130.55, 132.10 (d, ßJC 9.1 Hz), 134.94, 137.10, 145.60, 151.50, 152.22(C=N), 162.75(d, ßJC 248 Hz) Calcd. For (C₁₆H₁₂FNO₃S): C, 60.55; H, 3.83; N, 4.40; S, 10.12%. Found: C, 60.56; H, 3.81; N, 4.41; S, 10.10%.

5-(3-Fluorophenyl)-4-tosyloxazole (5d). Light yellow solid, mp 193-195 °C (Yield: 98%). IR (KBr) (υmax, cm⁻¹): 1590 (C=N) 1330, 1150 (S=O). ³H-NMR (400 MHz, DMSO-d₆): δ (ppm) 2.41(3H, S, CH₃), 7.47-7.48 (3H, m, HAr), 7.66 (1H, dd, ßJHH 12.1 Hz, ßJHH 8.0 Hz, HAr), 7.76-7.77 (2H, m, HAr), 8.75 (2H, d, ßJHH 8.0 Hz, HAr), 8.70 (1H, s, oxazole proton). ¹³C-NMR (100 MHz, DMSO-d₆): δ (ppm) 21.60 (CH₃), 116.25 (d, ßJC 24 Hz), 118.44 (d, ßJC 20 Hz), 125.71, 127.69 (d, ßJC 8.0 Hz), 128.34, 130.59, 131.43 (d ßJC 8.0 Hz), 135.77, 136.92, 145.73, 150.76, 152.50 (C=N), 162.14 (d, ßJC 242.0 Hz). Calcd. For (C₁₆H₁₂FNO₃S): C, 60.55; H, 3.83; N, 4.40; S, 10.12%. Found: C, 60.56; H, 3.81; N, 4.41; S, 10.10%.

5-(3-Chlorophenyl)-4-tosyloxazole (5e). Colorless crystals, mp 260-262 °C (Yield: 90%). IR (KBr) (υmax, cm⁻¹): 1609 (C=N) 1329, 1149 (S=O). ³H-NMR (400 MHz, DMSO-d₆): δ (ppm) 2.40 (3H, S, CH₃), 7.42 (2H, d, ßJHH= 8.0 Hz, HAr), 7.44-7.47 (3H, m, HAr), 7.60 (1H, s, HAr), 7.84 (2H, d, ßJHH 8.0 Hz, HAr), 8.60 (1H, s, oxazole proton). ¹³C-NMR (100 MHz, DMSO-d₆): δ (ppm) 21.26 (CH₃), 124.79 125.97, 127.94, 128.55, 129.74, 129.52, 132.52, 137.04, 138.12, 143.55, 146.15, 157.71(C=N) Calcd. For (C₁₆H₁₂ClNO₃S): C, 57.56; H, 3.64; N, 4.19; S, 9.60%. Found: C, 57.57; H, 3.62; N, 4.20; S, 9.61%.

5-(p-Tolyl)-4-tosyloxazole (5f). Dark brown solid, mp 281-282°C (Yield: 98%). IR (KBr) (υmax, cm⁻¹): 1597 (C=N) 1316, 1146 (S=O). ³H-NMR (400 MHz, DMSO-d₆): δ (ppm) 2.40, 2.41(6H, s, 2CH₃), 7.40 (2H,d, ßJHH= 8.1 Hz, HAr ),7.46 (2H, d, ßJHH 8.1 Hz, HAr ), 7.78-7.83 (4H, m, HAr), 8.84 (1H, s, oxazole proton); ¹³C-NMR (100 MHz, DMSO-d₆) 21.38, 21.57 (2CH₃), 125.67, 126.65, 128.25, 129.04, 129.67, 130.52, 132.11, 135.00, 137.25, 138.45, 145.51, 152.07, 152.44 (C=N). Calcd. For (C₁₇H₁₅NO₃S): C, 65.15; H, 4.82; N, 4.49; S, 10.25%. Found: C, 65.16; H, 4.82; N, 4.47; S, 10.23%.

5-(m-Tolyl)-4-tosyloxazole (5g). Dark brown solid, mp 270-272°C (Yield: 98%). IR (KBr) (υmax, cm⁻¹): 1594 (C=N) 1313, 1143 (S=O). ³H-NMR (400 MHz, DMSO-d₆): δ (ppm) 2.40 (6H, S, 2CH₃), 7.40 (1H,d, ßJHH 8.1 Hz, HAr), 7.45-7.47 (3H, m, HAr), 7.68 (1H, s, HAr), 7.71 (1H, d, ßJHH 8.1 Hz, HAr), 7.84 (2H,d, ßJHH 8.0 Hz, HAr), 8.64 (1H, s, oxazole proton). ¹³C-NMR (100 MHz, DMSO-d₆): δ (ppm) 21.38, 21.57 (2CH₃), 58.59 (OCH₃), 62.60 (OCH₂), 128.23, 128.60, 130.64, 137.58, 145.71, 152.18, 153.39 (C=N). Calcd. For (C₁₇H₁₅O₃S): C, 53.90; H, 4.91; N, 5.26; S, 11.99%. Found: C, 53.92; H, 4.90; N, 5.24; S, 12.00%.

5-(1,2-Dichloro-2-methylpropyl)-4-tosyloxazole (5i). Light brown powder, mp 180-182 °C (Yield: 98%). IR (KBr) (υmax, cm⁻¹): 1595 (C=N) 1326, 1148 (S=O). ³H- NMR (400 MHz, DMSO-d₆): δ (ppm) 1.21, 1.49, (6H, s, 2CH₃), 2.49, (3H, s, CH₃), 4.40 (1H, s, CH), 7.50 (2H, d, ßJHH 8.1 Hz, HAr), 7.90 (2H, d, ßJHH 8.1 Hz, HAr) 8.57 (1H, s, oxazole proton); ¹³C-NMR (100 MHz, DMSO-d₆): δ (ppm) 19.41, 21.61, 24.05 (3CH₃), 55.26, 62.64, 128.21, 130.71, 136.90, 138.24, 145.81, 151.30, 152.95(C=N) .Calcd. For (C₁₄H₁₃Cl₂NO₃S): C, 48.29; H, 4.32; N, 4.01; S, 9.23%. Found: C, 48.28; H, 4.34; N, 4.02; S, 9.21%.
Acknowledgements

We gratefully acknowledge, the Vail-e-Asr University of Rafsanjan Faculty Research Grant for financial support.

Supplementary Material

Copies of FT-IR, $^1$H and $^{13}$C NMR spectras for compounds 5a-I.

References

1. Semenyuta, I.; Kovalishyn, V.; Tanchuk, V.; Pilyo, S.; Zyabrev, V.; Blagodatnyy, V.; Trokhimenko, O.; Brovarets, V.; Metelytsia, L. *Comput. Biol. Chem.* **2016**, *65*, 8. https://doi.org/10.1016/j.compbiolchem.2016.09.012

2. Murade, C. U.; Subramaniam, V.; Otto, C.; Bennink, M. L. *Biophys. J.* **2009**, *97*, 835. https://doi.org/10.1016/j.bpj.2009.05.024

3. Eswaran, S.; Adhikari, A. V.; Ajay Kumar, R. *Eur. J. Med. Chem.* **2010**, *45*, 957. https://doi.org/10.1016/j.ejmech.2009.11.036

4. Stokes, N. R.; Baker, N.; Bennett, J. M.; Chauhan, P. K.; Collins, I.; Davies, D. T.; Gavade, M.; Kumar, D.; Lancett, P.; Macdonald, R.; Macleod, L.; Mahajan, A.; Mitchell, J. P.; Nayar, N.; Nayar, Y. N.; Pitt, G. R.; Singh, M.; Yadav, A.; Srivastava, A.; Czaklewski, L. G.; Haydon, D. J. *Bioorg. Med. Chem. Lett.* **2014**, *24*, 353. https://doi.org/10.1016/j.bmcl.2013.11.002

5. Norman, B. H.; Lee, L. F.; Masferrer, J. L.; Talley, J. J. *U.S. Patent*, 5380738 A, **1995**.

6. Fernandes, E.; Costa, D.; Toste, S. A.; Lima, J. L.; Reis, S. *Free Radic. Biol. Med.* **2004**, *37*, 1895. https://doi.org/10.1016/j.freeradbiomed.2004.09.001

7. Lu, X.; Liu, X.; Wan, B.; Franzblau, S. G.; Chen, L.; Zhou, C.; You, Q. *Eur. J. Med. Chem.* **2012**, *49*, 164. https://doi.org/10.1016/j.ejmech.2012.01.007

8. Moraski, G. C.; Chang, M.; Villegas- Estrada, A.; Franzblau, S. G.; Mollmann, U.; Miller, M. J. *Eur. J. Med. Chem.* **2010**, *45*, 1703. https://doi.org/10.1016/j.ejmech.2009.12.074

9. Rastogi, N.; Abdul, J., Goh, K. S.; Devallois, A.; Philogene, E.; Bourgeois, P. *FEMS Immunol. Med. Microbiol.* **1998**, *20*, 267. https://doi.org/10.1111/j.1574-695X.1998.tb01136.x

10. Sriram, D.; Yogeeswari, P.; Thirumurugan, R.; Pavana, R. K., *J. Med. Chem.* **2006**, *49*, 3448. https://doi.org/10.1021/jm060339h

11. Turchi, I. J.; Dewar, M. J. S. *Chem. Rev.* **1975**, *75*, 389. https://doi.org/10.1021/cr60339h

12. Wasserman, H. H.; Gambale, R. *J. J. Am. Chem. Soc.* **1985**, *107*, 1423. https://doi.org/10.1021/ja00291a059

13. Maryanoff, B. E. In *Heterocyclic Compounds*; Turchi, I. J., Ed.; Wiley & Sons: New York, 1986; Vol. 45, Chapter 5.

14. Kelly, T. R.; Lang, F. *J. Org. Chem.* **1996**, *61*, 4623. https://doi.org/10.1021/jo960433d
15. Panek, J. S.; Beresis, R. T. J. Org. Chem. 1996, 61, 6496. 
https://doi.org/10.1021/jo960532r
16. Wipf, P.; Miller, C. P. J. Org. Chem. 1993, 58, 3604. 
https://doi.org/10.1021/jo00066a004
17. Wipf, P.; Lim, S. J. Am. Chem. Soc. 1995, 117, 558. 
https://doi.org/10.1021/ja00106a075
18. Bagley, M. C.; Buck, R. T.; Hind, S. L.; Moody, C. J. Perkin Trans 1. 1998, 591. 
https://doi.org/10.1039/a704093h
19. Wipf, P.; Graham, T. H. J. Org. Chem. 2001, 66, 3242. 
https://doi.org/10.1021/jo005787q
20. Gabriel, S. Ber. Dtsch. Chem. Ges. 1910, 43, 1283. 
https://doi.org/10.1002/cber.19100430219
21. Robinson, R. J. Chem. Soc. 1909, 95, 2167. 
https://doi.org/10.1039/CT9099502167
22. Haung, W. S.; Zhang, Y. X.; Yaun, C. Y. Synth. Commun. 1996, 26, 1149. 
https://doi.org/10.1080/00397919608003722
23. Bossio, R.; Marcaccini, S.; Pepino, R. Heterocycles, 1986, 24, 3
https://doi.org/10.3987/R-1986-04-0983
24. Ozaki, Y.; Maeda, S.; Iwasaki, T.; Matsumoto, K.; Odawara, A.; Sasaki, Y.; Morita, T. Chem. Pharm. Bull. 1983, 12, 4417. 
https://doi.org/10.1248/cpb.31.4417
25. Ohba, M.; Kubo, H.; Seto, S.; Fujii, T.; Ishibashi, H. Chem. Pharm. Bull. 1998, 46, 860. 
https://doi.org/10.1248/cpb.46.860
26. Tang, J.; Varkade, J. G. J. Org. Chem. 1994, 59, 7793. 
https://doi.org/10.1021/jo00104a041
27. Sasaki, H.; Kitagawa, T. Chem. Pharm. Bull. 1988, 36, 1593. 
https://doi.org/10.1248/cpb.36.1593
28. Brahma, S.; Ray, J. K. J. Heterocycl. Chem. 2008, 45, 311. 
https://doi.org/10.1002/jhet.5570450203
29. Tiwari, D. K.; Pogula, J. RSC Adv. 2015, 5, 53111. 
https://doi.org/10.1039/C5RA07668D
30. Gouttebaron, R.; Cornelissen, D.; Snyders, R.; Dauchot, J. P.; Wautelet, M.; Hecq, M. JITF. 2000, 30, 527.
31. Li, B.; Buzon, R. A.; Zhang, Z. J. Org. Process Res. Dev. 2007, 11, 951. 
https://doi.org/10.1021/op070017n
32. Baumann, M.; Baxendale, I. R.; Ley, S. V.; Smith, C. D.; Tranmer, G. K. Org. Lett. 2006, 8, 5231. 
https://doi.org/10.1021/ol061975c
33. Miller, R. A.; Smith, R. M.; Marcune, B. J. Org. Chem. 2005, 70, 9074. 
https://doi.org/10.1021/jo051490m
34. Davies, J. R.; Kane, P. D.; Moody, C. J. Tetrahedron, 2004, 60, 3967. 
https://doi.org/10.1016/j.tet.2004.03.037
35. Xia, Q.; Ganem, B. Synthesis 2002, 1969.
36. Ohba, M.; Kubo, H.; Seto, S.; Fujii, T.; Ishibashi, H. Chem. Pharm. Bull. 1998, 46, 860. 
https://doi.org/10.1248/cpb.46.860
37. Matsumoto, K.; Suzuki, M.; Yoneda, N.; Miyoshi, M. Synthesis 1976, 805.
38. Possel, O.; Van Leusen, A. Heterocycles 1977, 7, 77.
39. van Leusen, A. M.; Hoogenboom, B. E.; Siderius, H. *Tetrahedron Lett.* **1972**, *13*, 2369.  
   https://doi.org/10.1016/S0040-4039(01)85305-3
40. Kulkarni, B. A.; Ganesan, A. *Tetrahedron Lett.* **1999**, *40*, 5637.  
   https://doi.org/10.1016/S0040-4039(99)01050-3
41. Schöllkopf, U.; Gerhart, E. *Angew. Chem., Int. Ed. Engl.* **1968**, *7*, 805.  
   https://doi.org/10.1002/anie.196808051
42. Schöllkopf, U.; Schröder, R. *Angew. Chem., Int. Ed. Engl.* **1971**, *10*, 333.  
   https://doi.org/10.1002/anie.197103331
43. Yeh, V. S. C. *Tetrahedron* **2004**, *60*, 11995.  
   https://doi.org/10.1016/j.tet.2004.10.001
44. Martin, R.; Cuenca, A.; Buchwald, S. L. *Org. Lett.* **2007**, *9*, 5521.  
   https://doi.org/10.1021/ol7024718
45. Herrera, A.; Martinez-Alvarez, R.; Ramiro, P.; Molero, D.; Almy, J. *J. Org. Chem.* **2006**, *71*, 3026.  
   https://doi.org/10.1021/jo052619v
46. Davies, J. R.; Kane, P. D.; Moody, C. J. *Tetrahedron* **2004**, *60*, 3967.  
   https://doi.org/10.1016/j.tet.2004.03.037
47. Shi, B.; Blake, A. J.; Campbell, I. B.; Judkins, B. D.; Moody, C. *J. Chem. Comm.* **2009**, *22*, 3291.  
   https://doi.org/10.1039/b903878g
48. Hu, Y.; Yi, R.; Wang, C.; Xin, X.; Wu, F.; Wan, B. *J. Org. Chem.* **2014**, *79*, 3052.  
   https://doi.org/10.1021/jo5001719
49. Ozaki, Y.; Maeda, S.; Iwasaki, T.; Matsumoto, K.; Odawara, A.; Sasaki, Y.; Morita, T. *Chem. Pharm. Bull.* **1983**, *31*, 4417.  
   https://doi.org/10.1248/cpb.31.4417
50. Marcus, Bauman, M.; Baxendale, I.R.; Ley, S.V.; Smith, C.D.; Tranmer, G.K. *Org. Lett.* **2006**, *8*, 5231.  
   https://doi.org/10.1021/ol061975c